Search Results - "Merchan, Brayan"

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol by Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Oñate, Guadalupe, Diaz-Beyá, Marina, Arnan, Montserrat, Tormo, Mar, Vives, Susana, de Llano, María Paz Queipo, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Garcia-Guiñon, Antonio, Salamero, Olga, Sampol, Antònia, Merchan, Brayan M., Bargay, Joan, Castaño-Díez, Sandra, Esteban, Daniel, Oliver-Caldés, Aina, Rivero, Andrea, Mozas, Pablo, López-Guerra, Mònica, Pratcorona, Marta, Zamora, Lurdes, Costa, Dolors, Rozman, Maria, Nomdedéu, Josep F., Colomer, Dolors, Brunet, Salut, Sierra, Jorge, Esteve, Jordi

“…The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to…”
Get full text

Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes by Montoro, Julia, Gallur, Laura, Merchán, Brayan, Molero, Antonieta, Roldán, Elisa, Martínez-Valle, Ferrán, Villacampa, Guillermo, Navarrete, Mayda, Ortega, Margarita, Castellví, Josep, Saumell, Silvia, Bobillo, Sabela, Bosch, Francesc, Valcárcel, David

“…The coexistence of autoimmune disorders (AD) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) has been widely…”
Get full text

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes by Caballero, Juan Carlos, Dávila, Julio, López-Pavía, María, Such, Esperanza, Bernal, Teresa, Ramos, Fernando, Calabuig, Marisa, Hernández Sánchez, Jesús María, Pomares, Helena, Sánchez Barba, Mercedes, Abáigar, María, González, Bernardo, Merchán, Brayan, Sancho-Tello, Reyes, Callejas, Marta, Muñoz-Novas, Carolina, Cerveró, Carlos, Sanz, Guillermo, Hernández Rivas, Jesús María, Díez Campelo, María

“…Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for…”
Get full text

Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes by Montoro, Julia, Pomares, Helena, Villacampa, Guillermo, Merchán, Brayan, Molero, Antonieta, Alonso, Esther, Gallur, Laura, Grau, Javier, Salamero, Olga, Roldán, Elisa, Saumell, Silvia, Ortega, Margarita, Sureda, Anna, Bosch, Francesc, Arnan, Montserrat, Valcárcel, David

“…In clinical practice, patients with myelodysplastic syndromes (MDS) are usually classified in low or high-risk groups to take therapeutic decisions,…”
Get full text

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA by Garcia-Gisbert, Nieves, Garcia-Ávila, Sara, Merchán, Brayan, Salido, Marta, Fernández-Rodríguez, Concepción, Gibert, Joan, Fernández-Ibarrondo, Lierni, Camacho, Laura, Lafuente, Marta, Longarón, Raquel, Espinet, Blanca, Vélez, Patricia, Pujol, Ramon M., Andrade-Campos, Marcio, Arenillas, Leonor, Salar, Antonio, Calvo, Xavier, Besses, Carles, Bellosillo, Beatriz

“…Molecular and cytogenetic studies are essential for diagnosis and prognosis in patients with myelodysplastic syndromes (MDSs). Cell-free DNA (cfDNA) analysis…”
Get full text

Comparative study to evaluate the wound healing efficacy of topical formulations containing Triticum aestivum L. (Triticum vulgare) in a native human skin model by Rojas, Brayan Styven Merchan, De-la-hoz, Jose Luis, Facchini, Gustavo, Silva, Gustavo Henrique da, Pinheiro, Ana Lúcia Tabarini Alves, Eberlin, Samara

“…Introduction: Plant extracts and actives derived from plants were developed to improve and enhance the skin healing process including Triticum aestivum L…”
Get full text

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial by Salamero, Olga, Somervaille, Tim C.P, Molero, Antonieta, Acuña-Cruz, Evelyn, Perez-Simon, Jose A., Coll, Rosa, Arnan, Montserrat, Merchan, Brayan, Perez, Ana, Cano, Isabel, Rodríguez-Veiga, Rebeca, Arevalo, Mabel, Gutierrez, Sonia, Buesa, Carlos, Faller, Douglas V, Bosch, Francesc, Montesinos, Pau

Get full text

Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes by Garcia-Gisbert, Nieves, Arenillas, Leonor, Roman-Bravo, David, Rodríguez-Sevilla, Juan José, Merchan, Brayan, Garcia-Avila, Sara, Fernández-Rodríguez, Concepción, Gibert, Joan, Salar, Antonio, Bellosillo, Beatriz, Ferrer, Ana, Calvo, Xavier

“…Introduction. Oligomonocytic chronic myelomonocytic leukemia (OM-CMML) is defined as those myelodysplastic syndromes (MDS) or MDS/MPN unclassifiable cases with…”
Get full text

Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML) by Roman-Bravo, David, Arenillas, Leonor, Asensi, Maria Teresa, Garcia-Gisbert, Nieves, Rodriguez-Sevilla, Juan Jose, Merchan, Brayan, García Ávila, Sara, Bellosillo, Beatriz, Fernández-Rodríguez, Concepción, Florensa, Lourdes, Ferrer, Ana, Calvo, Xavier

“…INTRODUCTION Recent studies have shown that OM-CMML and CMML have a similar clinical and biological profile. Since the proliferative-CMML (P-CMML) is the…”
Get full text

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial) by Salamero, Olga, Somervaille, Tim C.P, Molero, Antonieta, Acuña-Cruz, Evelyn, Pérez-Simón, Jose, Coll, Rosa, Arnan Sangerman, Montserrat, Merchan, Brayan, Perez, Ana, Cano, Isabel, Rodríguez-Veiga, Rebeca, Gutierrez, Sonia, Buesa, Carlos, Bosch, Francesc, Montesinos, Pau

“…Introduction: Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy. Elderly patients were historically treated with chemotherapy, with ORRs…”
Get full text

Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment by Roman, David, Arenillas, Leonor, Parraga, Ivonne, Florensa, Lourdes, Montesdeoca, Sara, Salido, Marta, Anna, Puiggros, Espinet, Blanca, Colomo, Lluís, Andrade, Marcio, Merchan, Brayan, Ferrer, Ana, Calvo, Xavier

“…Introduction The majority of prognostic indexes in CMML include information extracted from bone marrow (BM) evaluation. The blast count in BM in CMML includes…”
Get full text

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms by Andrade-Campos, Marcio M, Fernández-Ibarrondo, Lierni, Gibert, Joan, Fernández, Concepción, Merchan, Brayan, García Gisbert, Nieves, Camacho, Laura, Arenillas, Leonor, García Ávila, Sara, Longarón, Raquel, Salar, Antonio, Besses, Carles, Bellosillo, Beatriz

“…Background: Polycythemia vera (PV), Essential Thrombocytosis (ET) and Primary Myelofibrosis (PMF) are Myeloproliferative Neoplasms (MPNs) with median age at…”
Get full text

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study by Valcárcel, David, Dr, Sanz, Guillermo, MD, Ortega, Margarita, PhD, Nomdedeu, Benet, MD, Luño, Elisa, MD, Diez-Campelo, María, MD, Ardanaz, María Teresa, MD, Pedro, Carmen, MD, Montoro, Julía, MD, Collado, Rosa, MD, Andreu, Rafa, MD, Marco, Victor, MD, Cedena, María Teresa, MD, de Paz, Raquel, MD, Tormo, Mar, MD, Xicoy, Blanca, MD, Ramos, Fernando, MD, Bargay, Joan, MD, Gonzalez, Bernardo, MD, Brunet, Salut, MD, Muñoz, Juan Antonio, MD, Gomez, Valle, MD, Bailén, Alicia, MD, Sanchez, Joaquin, MD, Merchán, Brayan, MD, del Cañizo, Consuelo, Prof, Vallespí, Teresa, MD

“…Summary Background We aimed to compare the ability of recently developed prognostic indices for myelodysplastic syndromes to identify patients with poor…”
Get full text

Morphological central nervous system differentiation syndrome in acute promyelocytic leukemia relapse by Rodriguez‐Sevilla, Juan Jose, Calvo, Xavier, Garcia, Sara, Merchan, Brayan, Ferrer, Ana, Arenillas, Leonor

Get full text

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes by Garcia-Gisbert, Nieves, Merchan, Brayan, Garcia-Avila, Sara, Salido, Marta, Fernández-Rodríguez, Concepción, Gibert, Joan, Fernández-Ibarrondo, Lierni, Camacho, Laura, Lafuente, Marta, Longarón, Raquel, Espinet, Blanca, Vélez, Patricia, Andrade-Campos, Marcio M, Pujol, Ramon M., Arenillas, Leonor, Calvo, Xavier, Besses, Carles, Salar, Antonio, Bellosillo, Beatriz

“…Introduction. Myelodysplastic syndromes (MDS) are clonal heterogeneous disorders in which molecular studies and cytogenetics are essential for diagnosis,…”
Get full text

High Diagnostic Utility of Flow Cytometry Based Peripheral Blood Monocyte Subset Analysis, CD56 and CD2 Expression in Chronic Myelomonocytic Leukemia (CMML) by Calvo, Xavier, Parraga, Ivonne, Garcia-Gisbert, Nieves, Florensa, Lourdes, Montesdeoca, Sara, Fernández, Concepción, Salido, Marta, Puiggros, Anna, Espinet, Blanca, Bellosillo, Beatriz, Colomo, Lluís, Roman, David, Andrade Campos, Marcio, Merchan, Brayan, Ferrer, Ana, Arenillas, Leonor

“…INTRODUCTION The diagnosis of CMML according to WHO 2017 requires the presence of ≥1x109/L and ≥10% of monocytes in peripheral blood (PB). Establishing an…”
Get full text

Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML) and Chronic Myelomonocytic Leukemia (CMML) Show Similar Clinical, Morphological, Immunophenotypic and Molecular Features by Calvo, Xavier, Garcia-Gisbert, Nieves, Parraga, Ivonne, Florensa, Lourdes, Montesdeoca, Sara, Fernández, Concepción, Salido, Marta, Puiggros, Anna, Espinet, Blanca, Bellosillo, Beatriz, Colomo, Lluís, Roman, David, Andrade, Marcio, Merchan, Brayan, Ferrer, Ana, Arenillas, Leonor

“…INTRODUCTION The 2017 WHO classification requires the presence of ≥1x109/L and ≥10% of monocytes in peripheral blood (PB) for the diagnosis of CMML. Recently,…”
Get full text

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project) by Hoyos, Montserrat, Garrido, Ana, Arnan, Montserrat, Diaz-Beyá, Marina, Salamero, Olga, Vives, Susana, Garcia-Guiñon, Antonio, Gallardo, David, Cervera, Marta, Vall-Llovera, Ferran, Motlló, Cristina, Merchan, Brayan, Roig Martinez, Imma, Ortin, Xavier, Olivera, Pável E, Sureda Balari, Anna, Valcarcel, David, Ribera, Josep-Maria, Esteve, Jordi, Sierra, Jorge

“…Introduction:Acute myeloid leukemia (AML) real-world incidence has been investigated in a limited number of European countries such as Sweden, Denmark and a…”
Get full text

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival by Garrido, Ana, Hoyos, Montserrat, Diaz-Beyá, Marina, Arnan, Montserrat, Vives, Susana, Calabuig, Marisa, Salamero, Olga, Gallardo, David, Queipo De Llano, Maria Paz, Escoda, Lourdes, Sampol, Antonia, Vall-Llovera, Ferran, Garcia-Guiñon, Antonio, Brayan, Merchan, Bargay, Joan, Torres, J Pio, Ortin, Xavier, Amigo, M Luz, Moraleda, Jose Maria, Falantes, José F., Valcarcel, David, Tormo, Mar, Ribera, Josep-Maria, Brunet, Salut, Sureda Balari, Anna, Esteve, Jordi, Sierra, Jorge

“…The progress in the understanding of pathophysiology of AML has allowed the identification of genetic and immune abnormalities with prognostic impact on…”
Get full text

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories by Montoro, Maria Julia, Ortega, Margarita, Villacampa, Guillermo, Bernal, Teresa, Pomares, Helena, Mora Casterá, Elvira, Molero, Antonieta, Vilorio, Laura, Tormo, Mar, Diaz-Beyá, Marina, Brayan, Merchan, Jerez, Andres, Rivero, Eugenia, Lys, Maria Jose, Cárcel, Paula, Bargay, Joan, Ramos, Fernando, Xicoy, Blanca, Diez-Campelo, Maria, Valcarcel, David

“…▪ Introduction: Although the IPSS-R stratifies patients with MDS in five risk groups and includes an intermediate-risk group, treatment options are commonly…”
Get full text